June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Safety and efficacy of solid lipid nanoparticulate loaded atorvastatin topical application
Author Affiliations & Notes
  • Sai Bo Bo Tun
    Singapore Eye Research Institute/Singapore National Eye Centre, Singapore
  • Indu P. Kaur
    University Institute of Pharmaceutical Sciences, Panjab University, India
  • Sia Wey Yeo
    Singapore Eye Research Institute/Singapore National Eye Centre, Singapore
  • Tien Yin Wong
    Singapore Eye Research Institute/Singapore National Eye Centre, Singapore
    Eye-ACP, Duke-NUS Graduate Medical School, Singapore
  • Chi D Luu
    Centre for Eye Research Australia, The University of Melbourne, Victoria, Australia
    Singapore Eye Research Institute/Singapore National Eye Centre, Singapore
  • Veluchamy A Barathi
    Singapore Eye Research Institute/Singapore National Eye Centre, Singapore
    Eye-ACP, Duke-NUS Graduate Medical School, Singapore
  • Footnotes
    Commercial Relationships   Sai Bo Bo Tun, None; Indu P. Kaur, None; Sia Wey Yeo, None; Tien Wong, None; Chi Luu, None; Veluchamy Barathi, None
  • Footnotes
    Support  SHF/FG664P/2017_SERI-JRSHST170800
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3976. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sai Bo Bo Tun, Indu P. Kaur, Sia Wey Yeo, Tien Yin Wong, Chi D Luu, Veluchamy A Barathi; Safety and efficacy of solid lipid nanoparticulate loaded atorvastatin topical application. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3976.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A novel solid lipid nanoparticulate (SLN) drug delivery system has been developed to deliver drugs into the posterior segment of the eye via topical application. The purpose of this study was to investigate the safety and efficacy of SLN loaded atorvastatin (SLN-ATS) in a high-fat atherogenic mouse model of thickened Bruch’s membrane (a pathological feature of age-related macular degeneration, AMD).

Methods : Mice of C57BL/6J strain (6 weeks old; n=30) were divided into 6 groups of normal pellet diet (n=5), high-fat diet (HFD, n=5), HFD+atorvastatin (ATS) free suspension prevention (n=5), HFD+SLN-ATS prevention (n=5), HFD+ATS free suspension regression (n=5), HFD+SLN-ATS regression group (n=5). Both eyes received the formulations (0.25%) twice daily via topical route from day 0 for the prevention group or from week 15 for the regression group. Animals were monitored and weighed weekly during the experimental period. Retinal structure and function were examined at baseline, and at weeks 15 and 30 after treatment using optical coherence tomography and electroretinography (ERG), respectively. Eye tissues were collected at termination for gross histology and transmission electron microscopy of Bruch’s membrane (BM).

Results : There was no ocular abnormalities or systemic adverse effect noticed with the treatment. At week 30, the body weight was not significantly reduced in SLN groups as compared to HFD control group (p = 0.145). In mice treated with SLN+ATS, BM thickness was significantly reduced both in the prevention (0.55±0.38µm; p<0.01) and regression groups (0.96±0.28µm; n = 8 eyes; p<0.05) as compared to HFD group (1.98±0.46µm). There was no difference in ERG responses between SLN+ATS treated and control groups (p>0.05).

Conclusions : SLN safely delivers drug to the posterior segment via topical application. These findings suggest that SLN topical application could potentially be an alternative method for treating chronic retinal diseases such as neovascular AMD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×